Low risk of nosocomial severe acute respiratory syndrome-coronavirus-2 infection in patients with liver disease admitted to a hepatology unit at an academic hospital: A single-center experience

Indian J Gastroenterol. 2022 Jun;41(3):292-299. doi: 10.1007/s12664-022-01241-8. Epub 2022 Jun 30.

Abstract

Background: Patients with liver disease may be at increased risk of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection due to immune dysfunction. However, the risk of nosocomial SARS-CoV-2 infection in these patients remains unknown. This study aimed to determine whether patients with liver disease are at an increased risk of nosocomial transmission of SARS-CoV-2 infection upon admission to the hospital for diagnostic or therapeutic procedures.

Methods: The study prospectively enrolled 143 patients who were admitted at least once to the hepatology unit at our hospital; 95 patients (66%) were admitted at least twice during the study period. History of past symptomatic SARS-CoV-2 exposure was assessed on the day before hospital admission via an interview. Patients were evaluated for active SARS-CoV-2 infection via real-time reverse transcription-polymerase chain reaction (RT-PCR) performed on nasopharyngeal swabs and tests for serum anti-SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies.

Results: None of the patients enrolled tested positive for SARS-CoV-2 infection by RT-PCR at the first or the second clinical evaluation. One patient who had previously received a liver transplant and who had a history of symptomatic SARS-CoV-2 infection that occurred 4 months before hospital admission tested positive for anti-SARS-CoV-2 IgG but not IgM antibodies at each of the two hospital admissions.

Conclusions: The results of our study suggest that patients with liver disease are at no increased risk of nosocomial SARS-CoV-2 infection. These data support the policy of maintaining clinical hospital checks that will be necessary until or possibly even after the completion of the current SARS-CoV-2 vaccination campaign.

Keywords: Hepatocellular carcinoma; Immunoglobulin G; Immunoglobulin M; Immunosuppression; Liver cirrhosis; Liver transplantation; Nasopharyngeal swab; Nosocomial infection; Reverse transcriptase polymerase chain reaction; SARS-CoV-2 infection; Vaccination.

MeSH terms

  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19* / epidemiology
  • Cross Infection* / diagnosis
  • Cross Infection* / epidemiology
  • Digestive System Diseases*
  • Gastroenterology*
  • Hospitals
  • Humans
  • Immunoglobulin G
  • Immunoglobulin M
  • Liver Diseases* / epidemiology
  • SARS-CoV-2

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Immunoglobulin G
  • Immunoglobulin M